Latest News for: egfr

Edit

Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer

Pharmiweb 24 Feb 2026
The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma and large cell carcinoma.17  Among the most common driver mutations in NSCLC are alterations in EGFR, which is a ...
Edit

Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer (Johnson & Johnson)

Public Technologies 23 Feb 2026
The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma and large cell carcinoma.17Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine ...
Edit

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

PR Newswire 17 Feb 2026
... a real-world five-year OS of eight percent in the frontline setting, which is worse than patients with EGFR exon 19 deletions or L858R mutations, who have a real-world five-year OS of 19 percent.21.
Edit

J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research

PR Newswire 12 Feb 2026
EGFR-mutant NSCLC is driven by aberrant activation of EGFR signaling, and while EGFR-targeted therapies have dramatically improved outcomes over the past decade, acquired resistance remains inevitable for most, if not all patients.
Edit

EGFR Non Small Cell Lung Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial ...

GetNews 12 Feb 2026
The EGFR Non Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase ... EGFR Non Small Cell Lung Cancer Overview.
Edit

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

PR Newswire 11 Feb 2026
EGFR-NSCLC Market Summary The market size for EGFR-NSCLC was found to be USD 6 billion in the leading markets in 2024 ... The total number of incident cases of EGFR-NSCLC in the leading market was nearly 117,000 in 2024 ... What is EGFR-NSCLC?.
Edit

EGFR + NSCLC Clinical Trial Pipeline Expands as 25+ Companies Driving Innovation in the Therapeutics ...

GetNews 09 Feb 2026
Inactive Products EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Companies EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Products EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Unmet Needs ...
Edit

Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients

PR Newswire 22 Jan 2026
... HT-001 in cancer patients receiving EGFR inhibitor therapy ... EGFR inhibitors are cornerstone therapies across multiple major cancer indications, including lung, colorectal, and head-and-neck cancers.
Edit

HANSOH PHARMA | AMEILE’S FIFTH INDICATION FOR “TARGETED THERAPY PLUS CHEMOTHERAPY” APPROVED, MARKING FULL-COURSE COVERAGE OF CHINA’S ORIGINAL THIRD-GENERATION EGFR-TKI (Hansoh Pharmaceutical Group Co Ltd)

Public Technologies 12 Jan 2026
AMEILE'S FIFTH INDICATION FOR "TARGETED THERAPY PLUS CHEMOTHERAPY" APPROVED, MARKING FULL-COURSE COVERAGE OF CHINA'S ORIGINAL THIRD-GENERATION EGFR-TKI ... Ameile is the first original third-generation EGFR-TKI innovative drug in China.
Edit

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

Nasdaq Globe Newswire 08 Jan 2026
- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated Q3 2026 – ... .
Edit

EGFR Inhibitors-Induced Skin Disorders Market Size in the 7MM is expected to increase at a ...

GetNews 08 Jan 2026
Discover Key Insights into the EGFR Inhibitors-Induced Skin Disorders Market with DelveInsight's In-Depth Report @ ... Nearly 20% of patients are affected with EGFR mutation in NSCLC ... EGFR Inhibitors-Induced Skin Disorders Emerging Drugs LUT014.
Edit

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

PR Newswire 18 Dec 2025
... targeted therapy for patients with EGFR+ mNSCLC ... Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC – Final Overall Survival from MARIPOSA [ELCC abstract #40].
Edit

Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma (Glenmark Pharmaceuticals Limited)

Public Technologies 16 Dec 2025
) Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma ... our ability to serve patients with EGFR-mutated lung cancer.
Edit

‘I am 74; recent blood report shows my kidney function (eGFR) as 53. How can I bring it to a normal level > 59?’

Indian Express 11 Dec 2025
Get kidney tests every 6-12 months .
Edit

RYBREVANT®▼(amivantamab) in combination with carboplatin and pemetrexed is accepted for use within NHS Scotland as a first-line treatment for adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations

Pharmiweb 09 Dec 2025
“EGFR+ UK is delighted that the Scottish Medicines Consortium has approved amivantamab with chemotherapy for eligible patients in Scotland diagnosed with EGFR Exon 20 insertion mutations NSCLC,” said Prof.

Article Search

tools
×
×
×
×